Mariana Brütt Pacheco

Ms. Mariana Brütt Pacheco

Portuguese Institute of Oncology of Porto
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPMariana Brütt Pacheco
Mariana Brütt Pacheco
VCVânia Camilo
Vânia Camilo
NLNair Lopes
Nair Lopes
FMFilipa Moreira-Silva
Filipa Moreira-Silva
MCMargareta Correia
Margareta Correia
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Among the well-established alterations contributing to prostate cancer (PCa) pathogenesis, epigenetics is an important player in its development and aggressive disease state. Moreover, since no curative therapies are available for advanced stage disease, there is an urgent need for novel therapeutic strategies targeting this subset of patients. Thus, we aimed to evaluate the combined antineoplastic effects of DNA methylation inhibitor hydralazine and histone deacetylase inhibitors panobinostat and valproic acid in several prostate cell lines. The effect of these drugs was assessed in four PCa (LNCaP, 22Rv1, DU145 and PC-3) cell lines, as well as in non-malignant epithelial (RWPE-1) and stromal (WPMY-1) cell lines, using several assays to evaluate cell viability, apoptosis, proliferation, DNA damage and clonogenic potential. We found that exposure to each epidrug separately reduced viability of all PCa cells in a dose-dependent manner and that combined treatments led to synergic growth inhibitory effects, impacting also on colony formation, invasion, apoptotic and proliferation rates. Interestingly, antitumoral effects of combined treatment were particularly expressive in DU145 cells. We concluded that hydralazine and panobinostat attenuate malignant properties of PCa cells, constituting a potential therapeutic tool to counteract PCa progression.

7 August 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
NLNair Lopes
Nair Lopes
MPMariana Brütt Pacheco
Mariana Brütt Pacheco
DSDiana Soares-Fernandes
Diana Soares-Fernandes
MCMargareta Correia
Margareta Correia
VCVânia Camilo
Vânia Camilo
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combination of hydralazine, a DNA methylation inhibitor, with enzalutamide, an antagonist of the androgen receptor, in prostate cancer cell lines. Several biological parameters, such as cell viability, proliferation, DNA damage, and apoptosis, as well as clonogenic and invasive potential, were evaluated. The individual treatments with hydralazine and enzalutamide exerted growth-inhibitory effects in prostate cancer cells and their combined treatment displayed synergistic effects. The combination of these two drugs was very effective in decreasing malignant features of prostate cancer and may become an alternative therapeutic option for prostate cancer patient management.

15 June 2021 in Epigenetics
Verified
Journal Article
Closed access
MPMariana Brütt Pacheco
Mariana Brütt Pacheco
VCVânia Camilo
Vânia Camilo
Rui HenriqueRui Henrique
Rui Henrique
Carmen JeronimoCarmen Jeronimo
Carmen Jeronimo
Epigenome editing consists of fusing a predesigned DNA recognition unit to the catalytic domain of a chromatin modifying enzyme leading to the introduction or removal of an epigenetic mark at a specific locus. These platforms enabled the study of the mechanisms and roles of epigenetic changes in several research domains such as those addressing pathogenesis and progression of cancer. Despite the continued efforts required to overcome some limitations, which include specificity, off-target effects, efficacy, and longevity, these tools have been rapidly progressing and improving. Since prostate cancer is characterized by multiple genetic and epigenetic alterations that affect different signalling pathways, epigenetic editing constitutes a promising strategy to hamper cancer progression. Therefore, by modulating chromatin structure through epigenome editing, its conformation might be better understood and events that drive prostate carcinogenesis might be further unveiled. This review describes the different epigenome engineering tools, their mechanisms concerning gene’s expression and regulation, highlighting the challenges and opportunities concerning prostate cancer research.